Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. vinge advises Enfo in connection with acquisition of Next Improvement
Mandate

vinge advises Enfo in connection with acquisition of Next Improvement

January 18, 2016

Vinge has advised Enfo in connection with its acquisition of the Swedish company, Next Improvement. Next Improvement is a turnkey supplier to businesses which want to improve efficiency, reduce costs and provide quality assurance in respect of their operations.

Next Improvement’s customer base is in Sweden and parts of Europe and its customers are primarily small and large companies within the industrial sector.

Vinge’s team consisted of partner Christina Kokko together with, among others, associates Linda Sengul, Maria Dahlin, Lova Unge, Mathilda Persson, Samra Baytar and Manne Bergström.  

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026